This Is My Highest-Conviction Stock to Own in 2023 and Beyond

This Is My Highest-Conviction Stock to Own in 2023 and Beyond·Motley Fool
In this article:

While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.

Advertisement